Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: Predictors and implications for adjuvant chemoradiotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 6, 2012, Pages 1063-1071

  Zhang, Yaojun ^a   Frampton, Adam E ^a   Kyriakides, Charis ^a   Bong, Jan J ^a   Habib, Nagy ^a   Ahmad, Raida ^b   Jiao, Long R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Pancreatic ductal adenocarcinoma; Pancreaticoduodenectomy; Predictors; Recurrence; Survival

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISTANT RECURRENCE; FEMALE; FOLLOW UP; HUMAN; LOCO RECURRENCE; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RESECTION MARGIN; RETROSPECTIVE STUDY; SURVIVAL AFTER RECURRENCE; TREATMENT INDICATION; TREATMENT REFUSAL; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84864363239     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1165-7     Document Type: Article

References (35)

1. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP (2004) Current standards of surgery for pancreatic cancer. Br J Surg 91(11):1410-1427. doi:10.1002/bjs.4794
2. Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A, Salvia R, Bassi C, Pederzoli P (2007) The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP 8(1 Suppl):132-140
3. BSG (2005) Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 54(Suppl 5): v1-v16. doi:10.1136/gut.2004.057059
4. Campbell F, Foulis AK, Verbeke CS (2010) The Royal College of pathologists. standards and minimum datasets for reporting cancers. Minimum Dataset for the Histopathological Reporting of Pancreatic, Ampulla of Vater and Bile Duct Carcinoma. http://www.rcpath.org/resources/pdf/ datasethistopathologicalreporting carcinomasmay10.pdf
5. Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, Haglund C (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54(3):385-387. doi:10.1136/gut.2004.047191
6. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RW, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG, Biankin AV (2009) Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 27(17): 2855-2862. doi:10.1200/JCO.2008.20.5104
7. Choti MA (2004) Adjuvant therapy for pancreatic cancer-the debate continues. N Engl J Med 350(12):1249-1251. doi:10.1056/NEJMe048002
8. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL (2008) Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 26(21):3511-3516. doi:10.1200/JCO.2007.15. 8782
9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edn. Springer, Chicago
10. Fatima J, Schnelldorfer T, Barton J, Wood CM, Wiste HJ, Smyrk TC, Zhang L, Sarr MG, Nagorney DM, Farnell MB (2010) Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg 145(2):167-172. doi:10.1001/archsurg.2009.282
11. Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56(8):1134-1152. doi:10.1136/gut.2006.103333
12. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267. doi:10.1371/journal. pmed.1000267
13. GITSG GTSG (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59(12):2006-2010
14. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr, Yeo C, Cameron JL, Schulick RD, Abrams R (2008) Analysis of Xuorouracil- based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26(21):3503-3510. doi:10.1200/JCO.2007.15.8469
15. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC (2010) Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 17(4):981-990. doi:10.1245/s10434-009-0743-7
16. Iott M, Neben-Wittich M, Quevedo JF, Miller RC (2010) Adjuvant chemoradiotherapy for resected pancreas cancer. World J Gastrointest Surg 2(11):373-380. doi:10.4240/wjgs.v2.i11.373
17. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300. doi:10.3322/caac.20073
18. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J (1999) Adjuvant radiotherapy and 5-Xuorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230(6):776-782 (discussion 782-774)
19. Lancet T (2011) Pancreatic cancer in the UK. Lancet 378(9796):1050. doi:10.1016/S0140-6736(11)61465-7
20. Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a populationbased, linked database analysis of 396 patients. Ann Surg 237(1):74-85. doi:10.1097/01.SLA.0000041266. 10047.38
21. NCCN NCCN (2011) Clinical practice guidelines in oncology: pancreatic adenocarcinoma. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
22. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200-1210. doi:10.1056/NEJMoa032295 Neoptolemos
23. JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with Xuorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073-1081. doi:10.1001/jama.2010.1275
24. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267-277. doi:10.1001/jama.297.3.267
25. PCUK PCU (2011) Study for survival 2011. http://www.pancreaticcancer. org.uk/media/100292/report-final-for-web.pdf
26. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246(1):52-60. doi:10.1097/01.sla.0000259391.84304.2b
27. Regine WF, Abrams RA (2006) Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol 33(6 Suppl 11):S10-S13. doi:10.1053/j.seminoncol.2006.10.005
28. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA (2008) Fluorouracil vs. gemcitabine chemotherapy before and after Xuorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299(9):1019-1026. doi:10.1001/jama.299.9.1019
29. Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S (2005) Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas 31(1):69-73
30. Sommerville CA, Limongelli P, Pai M, Ahmad R, Stamp G, Habib NA, Williamson RC, Jiao LR (2009) Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors. J Surg Oncol 100(8):651-656. doi:10.1002/jso.21390
31. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP (2005) Metaanalysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92(8):1372-1381. doi:10.1038/sj.bjc.6602513
32. Verbeke CS (2008) Resection margins and R1 rates in pancreatic cancer- are we there yet? Histopathology 52(7):787-796. doi:10.1111/j.1365-2559.2007. 02935.x
33. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791):607-620. doi:10.1016/S0140-6736(10)62307-0
34. Williamson RC (1994) Operative surgery and management. In: Keen G, Farndon JR (eds) The pancreas, 3rd edn. Butterworth Heinemann, Oxford, pp 161-185
35. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199-1210 (discussion 1210-1191). doi:10.1016/j.gassur.2006.08.018